* If you want to update the article please login/register
"The investigators will co-create Tele-Navigation of Lung Cancer Screening with patients and LCS participants as an effort to encourage LCS compliance. " "Within 180 days from Tele-Navi LCS, the investigators will determine the number of patient participants who completed Tele-Navi LCS and a follow-up LCS. ".
Source link: https://clinicaltrials.gov/ct2/show/NCT05021133
"Lung cancer is the most common cause of cancer deaths worldwide. " Multiple randomized trials have shown that annual or biennial low-dose CT screening reduces lung cancer mortality. Women with a minimum of 25 pack-year smoking history who quit smoking less than 15 years ago will be eligible for baseline, 1-year, and 2-year low-dose CT of the chest. According to the European lung cancer screening initiative, the CT scans will be read on site by a general radiologist trained to lung cancer screening, first without being aided by an artificial device developed to lung nodule detection. The reasons for positive screen result are as follows: solid nodule > 500 mm3 or increasing, part-solid nodule with > 8 mm solid component or new or increasing, pure ground glass nodule developing a large percentage.
Source link: https://clinicaltrials.gov/ct2/show/NCT05195385
"To determine the clinical relevance of circulating tumor DNA within the plasma cell-free DNA from early stage lung cancer patients," says the author. Patients with a mutation associated with one or two of the investigational drugs used in this research, as well as those with no mutations are enrolled in one of the four treatment subprotocols. On days 1-21, blinded patients receive erlotinib hydrochloride orally every day. Patients are on days 1-21 with placebo PO QD. Patients receive crizotinib PO twice a day on days 1-21. Patients are treated with one of the 4 platinum doublet regiment regimens* based on the treating physician's preference. Patients are treated with one of the following four platinum doublet regiment regimens* based on the treating physician's preference and penetrogramab IV over 25-40 minutes on day 1. On day 1, patients are then treated to pemolizumab IV over 25-40 minutes, which is then confirmed by CONTINUANCE THERAPY: Patients are then treated to petolizumab IV over 25-40 minutes. On day 1 of each cycle, patients are given cisplatin IV over 1-2 hours and penet IV over ten minutes. Patients on day 1 of each cycle, with carboplatin IV administered over 30 minutes and peneted IV over ten minutes. Patients receive cisplatin IV over 1-2 hours on day one of each cycle and gemcitabine hydrochloride IV over 30 minutes on days 1 and eight of each cycle, as seen on page 1 and 8. Patients on day 1 of each cycle receive carboplatin IV over 30 minutes and paclitaxel IV over three hours.
Source link: https://clinicaltrials.gov/ct2/show/NCT02194738
"To determine the effect of metformin therapy on the expression of programmed cell death protein 1 in overweight and obese individuals at a risk for lung cancer," says the author. " During the waiting period, estimates of PD-1 change in Cohort B was estimated based on the wait period. The aim of this research is to determine the effects of metformin on blood lymphocyte subsets. To investigate the effect of metformin on the immune profile of pulmonary parenchyma portrayed by bronchoalveolar lavage bronchoalveolar lavage. Participants are treated with metformin extended release orally for 26 weeks in the absence of unacceptable toxicology. ".
Source link: https://clinicaltrials.gov/ct2/show/NCT04931017
"Based on the national cancer survey results in 2020, Florida has the highest lung cancer incidence with the most deaths in all the states. " Unfortunately, around 16% of adults in Florida continue to smoke cigarettes due to its addictive nature and the skepticism of existing cessation programs. This report will also investigate whether kava use can reduce tobacco use and dependence, as well as tobacco-associated lung carcinogenesis. ".
Source link: https://clinicaltrials.gov/ct2/show/NCT05081882
"Evaluate whether immunostaining of induced sputum specimens improves the sensitivity and specificity of routine morphologic sputum analysis to detect second primary lung cancer in patients with previously diagnosed nonsmall cell lung cancer. " Evaluate which patients are at risk of developing a second primary lung cancer by immunostaining specimens from patients with no morphological atypia of routine Papanicolaou cytology. Evaluate whether analysis of elevations of relevant growth factors in bronchial lavage fluid from patients with positive immunostaining or morphologic atypia improves the likelihood of early detection. Evaluate whether quantitation of shed antigens in sputum improves early detection's success. Evaluate whether the severity of airway obstruction, as determined by the forced expiratory volume, can suggest an elevated risk of lung cancer. OUTLINE: Screening for the second primary lung cancer type. "In the first 100 patients, the sample size will be adjusted based on the rate of positive staining.
Source link: https://clinicaltrials.gov/ct2/show/NCT00002667
"The purpose of phase II is the confirmation of antibodies in patients who were positive in Phase I of the study, a few weeks after the first diagnosis was made using the SOLID method. " The confirmation of antibodies in patients with lung cancer who have been vaccinated with any of the available and approved vaccines for SARS-COV2 and 6 months after the government's intervention is the focus of phase III.
Source link: https://clinicaltrials.gov/ct2/show/NCT04407143
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions